Business Context and Reporting Period
Company: TherapeuticsMD, Inc. (TXMD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Model: Following a 2022 transformation, the company operates as a pharmaceutical royalty entity. It no longer conducts commercial operations, which are reported as discontinued operations. Revenue is derived primarily from royalties and milestone payments on products (IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins) licensed to Mayne Pharma (U.S.) and other partners (Theramex, Knight) internationally.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| License Revenue | $869 | $1,593 |
| Total Operating Expenses | $1,685 | $3,132 |
| Loss from Operations | $(816) | $(1,539) |
| Net Income (Loss) | $155 | $250 |
| Cash and Cash Equivalents | $9,189 | $9,189 (Ending Balance) |
| Net Cash Provided by Operating Activities | N/A | $1,723 |
| Total Assets | $37,529 | $37,529 (Ending Balance) |
| Total Liabilities | $10,397 | $10,397 (Ending Balance) |
Note: The company reported a net income for the quarter and six-month period primarily due to "Other income" (sublease income, interest, and miscellaneous income) offsetting the operating loss. Operating margins remain negative.
Material Changes vs. Prior Period
- Revenue: License revenue decreased by $83,000 (8.7%) in Q2 2026 compared to Q2 2025 ($869k vs. $952k). However, for the six-month period, revenue increased by $248,000 (18.4%) to $1.593 million.
- Operating Expenses: Total operating expenses increased slightly in Q2 2026 ($1.685M vs. $1.647M) due to higher rent and press release costs. For the six-month period, expenses decreased by $189,000 (5.7%) primarily due to lower patent write-offs ($13k in 2026 vs. $88k in 2025) and reduced professional fees.
- Profitability: Net income for Q2 2026 was $155,000 ($0.01/share), a decrease from $551,000 ($0.05/share) in Q2 2025. This decline was driven by lower miscellaneous income and royalty sales of ANNOVERA, partially offset by higher sublease income.
- Cash Flow: Net cash provided by continuing operating activities increased significantly to $1.723 million for the six months ended June 30, 2026, compared to $1.080 million in the prior year period, driven by cash received from royalty receivables.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to reliance on royalty income, potential declines in Mayne Pharma's sales, and the uncertainty of the net working capital settlement.
- Legal Proceedings (Mayne Pharma): A significant dispute exists regarding net working capital allowances (payer rebates, distributor fees, and returns) from the 2022 transaction.
- TherapeuticsMD filed a lawsuit against Mayne Pharma in April 2025; Mayne filed a countersuit in May 2025.
- In May 2026, the court ordered the parties to submit net working capital claims to a dispute resolution process while staying the lawsuit.
- Management believes no additional accrual is required for potential losses as the range cannot be reasonably estimated.
- Patent Litigation: Ongoing Paragraph IV litigation against Teva and Sun Pharma regarding generic versions of IMVEXXY. The company has capitalized $2.334 million in legal costs, which will be expensed if the litigation is unsuccessful.
- Subsequent Event: In July 2026, Knight Therapeutics achieved a sales milestone for IMVEXXY, entitling the company to a $364.8 thousand payment, recognized in the quarter ending September 30, 2026.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to fund operations without additional equity financing, given the explicit "substantial doubt" disclosure.
- Mayne Pharma Dispute Resolution: Monitor the outcome of the dispute resolution process regarding net working capital allowances, as a negative outcome could result in significant unexpected liabilities.
- Patent Litigation Outcome: Assess the risk of expensing the $2.334 million in capitalized legal fees if the IMVEXXY patent defense against Teva or Sun Pharma fails.
- Revenue Concentration: Confirm that 100% of license revenue remains dependent on Mayne Pharma, Theramex, and Knight, with no diversification in the near term.
- Cash Burn vs. Royalty Inflow: Compare the $9.2 million cash balance against the quarterly operating cash burn and the timing of minimum annual royalty payments from Mayne Pharma.